Header Logo

Connection

SUSAN BLANEY to Aniline Compounds

Back to Details
This is a "connection" page, showing publications SUSAN BLANEY has written about Aniline Compounds.
SUSAN BLANEY
Connection Strength
0.014
Aniline Compounds
  1. Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101. Cancer Chemother Pharmacol. 2004 Jun; 53(6):482-8.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.